Studies of Cardiotonic Agents. 8. Synthesis and Biological Activities of Optically Active 6-(4-(Benzylamino)-7-quinazolinyl)-4,5-dihydro-5-methyl- 3(2H)-pyridazinone (KF15232)

Authors:

Abstract
We previously reported that (±)-6-(4-(benzylamino)-7-quinazolinyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone ((±)-1, KF15232) showed potent cardiotonic activity with a strong myofibrillar Ca2+-sensitizing effect. As an extension of our work, we attempted to synthesize optically active 1. (±)-4-(4-(Benzylamino)-7-quinazolinyl)-3-methyl-4-oxobutyric acid (−)-menthyl ester (6) was separated into both diastereoisomers, and each was converted to optically pure 1 (>99% ee) in an enantioselective manner. In order to determine the absolute configuration of the isomers, an alternative synthesis of optically active 1 was employed. The precursor of (−)-1 ((+)-9) was obtained by enantioselective synthesis from (R)-d-alanine. Consequently, we concluded that the absolute configuration of (−)-1 at the 5-position of the pyridazinone ring was R. The cardiotonic effects and inhibitory activities to PDE III and V of racemic 1 and (−)-1 were more potent than those of (+)-1. These compounds also demonstrated greater vasorelaxant effects in guinea pig aorta. In contrast, (+)-1 showed only weak cardiotonic and vasodilating effects, although the compound displayed potent Ca2+-sensitizing activity. Racemic and (−)-1 attracted our interest for the treatment of congestive heart failure.

This publication has 8 references indexed in Scilit: